$0.0190
+0 (+0%)
At Close: May 13, 2024
Invitae Corporation (NYSE: NVTA): Can The Stock Still Lose Despite An -41.26% YTD Loss?
08:00pm, Friday, 04'th Mar 2022 Marketing Sentinel
Invitae Corporation (NYSE:NVTA)’s traded shares stood at 1.77 million during the latest session, with the company’s beta value hitting 1.85. At the last check today, the stock’s price was $8.48, to imply a decrease of -5.46% or -$0.49 in intraday trading. The NVTA share’s 52-week high remains $43.99, putting it -418.75% down since that peak … Invitae Corporation (NYSE: NVTA): Can The Stock Still Lose Despite An -41.26% YTD Loss? Read More »
Astounding Stock: Waitr Holdings Inc. (NASDAQ:WTRH), Invitae Corporation (NYSE:NVTA)
10:13am, Thursday, 03'rd Mar 2022 Stock Equity
Waitr Holdings Inc. (NASDAQ:WTRH) with the stream of -0.77% also noticed, India Invitae Corporation (NYSE:NVTA) encountered a rapid change of -13.02% in the last hour of Wednesday’s trading session. Waitr … The post Astounding Stock: Waitr Holdings Inc. (NASDAQ:WTRH), Invitae Corporation (NYSE:NVTA) appeared first on Stocks Equity .
Invitae Corporation 2021 Q4 - Results - Earnings Call Presentation
03:57pm, Friday, 25'th Feb 2022 Seeking AlphaInvitae Corporation (NYSE:NVTA) 9.47% Above Its 52-Week Low, How Long Will It Keep Rising?
02:30pm, Friday, 25'th Feb 2022 Marketing Sentinel
In last trading session, Invitae Corporation (NYSE:NVTA) saw 8.16 million shares changing hands with its beta currently measuring 1.84. Company’s recent per share price level of $9.40 trading at $0.82 or 9.56% at ring of the bell on the day assigns it a market valuation of $2.21B. That closing price of NVTA’s stock is at … Invitae Corporation (NYSE:NVTA) 9.47% Above Its 52-Week Low, How Long Will It Keep Rising? Read More »
Invitae Shares Fall As Q4 Earnings Fall Short Of Street Expectation
12:25pm, Friday, 25'th Feb 2022 Benzinga
Invitae Corp''s (NASDAQ: NVTA ) Q4 FY21 revenues increased 26% Y/Y to $126.1 million, just shy of the consensus Wall Street estimate of $126.65 million. Invitae reported testing revenue of $121.6 million for the quarter and $4.5 million in other revenue. It billed for 327,000 tests in Q4 FY21. On an adjusted basis, the company reported an EPS loss of $(0.81), wider than analysts'' average estimate of a loss … Full story available on Benzinga.com
Invitae (NVTA) Q4 2021 Earnings Call Transcript
05:00am, Friday, 25'th Feb 2022 The Motley Fool
NVTA earnings call for the period ending December 31, 2021.
Invitae (NVTA) Q4 2021 Earnings Call Transcript
05:00am, Friday, 25'th Feb 2022 The Motley Fool
NVTA earnings call for the period ending December 31, 2021.
Invitae''s (NVTA) CEO Sean George on Q4 2021 Results - Earnings Call Transcript
12:55am, Friday, 25'th Feb 2022 Seeking AlphaInvitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates
11:10pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Invitae (NVTA) delivered earnings and revenue surprises of -9.46% and 1.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Invitae sees quarterly net loss narrow but still misses on bottom line (NYSE:NVTA)
09:37pm, Thursday, 24'th Feb 2022 Seeking Alpha
Although Invitae (NVTA) saw its Q4 2021 net loss narrow 12% compared to the prior-year period, the company still missed consensus on the bottom line.
Invitae Non-GAAP EPS of -$0.81 misses by $0.04, revenue of $126.1M beats by $0.2M
09:16pm, Thursday, 24'th Feb 2022 Seeking Alpha
Invitae press release (NVTA): Q4 Non-GAAP EPS of -$0.81 misses by $0.04.Revenue of $126.1M (+25.6% Y/Y) beats by $0.2M.Shares -0.43% AHGuidance: The company has issued 2022…
This Week's 5 Must-See Earnings Charts
03:56pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Will earnings matter for these 5 trending stocks?
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
01:01pm, Thursday, 24'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Adagio Appoints COO David Hering As Interim CEO
Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th
This Week's 5 Must-See Earnings Charts
12:20pm, Thursday, 24'th Feb 2022
Will earnings matter for these 5 trending stocks?
Sign In
Buy NVTA